Ligand Pharmaceuticals Inc (LGND) Stock Price & Analysis
Ligand Pharmaceuticals Inc (LGND) rose 2.33% to USD 243.28 as of June 10, 2026 at 05:13 UTC, according to Nexqual real-time market data.
LGND last closed at USD 237.75; the session ranged USD 237–244.84 on volume of 170,817 shares. Market capitalization is $4.88B, with a 52-week range of USD 110–247.38 (NGM). Source: Nexqual, June 10, 2026 at 05:13 UTC.
Key Statistics (as of June 10, 2026 at 05:13 UTC)
| Price | USD 243.28 |
|---|---|
| Change | ▲ 2.33% (up) |
| Previous Close | USD 237.75 |
| Open | USD 241.98 |
| Day Range | USD 237 – 244.84 |
| 52-Week Range | USD 110 – 247.38 |
| Volume | 170,817 shares |
| Market Cap | $4.88B |
| Exchange | NGM |
Technical Analysis (LGND)
Nexqual's technical model rates LGND "BUY" based on 5 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 05:13 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.12 (neutral) |
| vs SMA50 | Above (USD 221.85) |
| MACD | 4.34 (positive) |
Analyst Ratings (LGND)
Wall Street analysts rate LGND "Strong Buy" based on 10 analysts, with a mean price target of USD 277.6 (range USD 247–330), per Nexqual as of June 10, 2026 at 05:13 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 277.6 |
| High Target | USD 330 |
| Low Target | USD 247 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (LGND)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 1.99 |
| Revenue Estimate | $63.33M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.63 vs est 1.8 ▼ miss |
| 2025-12-31 | USD 2.02 vs est 1.5 ▲ beat |
| 2025-09-30 | USD 3.09 vs est 1.93 ▲ beat |
| 2025-06-30 | USD 1.6 vs est 1.42 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:13 UTC.
Financials & Fundamentals (LGND)
| Total Revenue | $274.48M |
|---|---|
| Revenue Growth (YoY) | +14.10% |
| Gross Margin | +83.16% |
| Operating Margin | +33.58% |
| Profit Margin | +55.95% |
| ROE | +17.13% |
| Debt / Equity | 45.32 |
| Current Ratio | 21.28 |
| Total Cash | $779.40M |
| Total Debt | $451.98M |
| Free Cash Flow | $142.11M |
Source: Nexqual, June 10, 2026 at 05:13 UTC.
Financial Health Score (LGND)
Nexqual rates Ligand Pharmaceuticals Inc's overall financial health "Strong" across five dimensions, as of June 10, 2026 at 05:13 UTC.
| Growth | Strong — Revenue +60% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 83%, operating 34% |
| Balance Sheet | Strong — $779M cash vs $452M debt, net cash position |
| Cash Flow | Strong — FCF $142M, 53% margin |
| Efficiency | Solid — ROE 17%, ROA 5.2% |
Ownership (LGND)
| Insider Ownership | +2.40% |
|---|---|
| Institutional Ownership | +106.33% |
| Shares Outstanding | 20.04M |
| Float | 19.57M |
| Short % of Float | +9.79% |
Source: Nexqual, June 10, 2026 at 05:13 UTC.
Leadership (LGND)
Ligand Pharmaceuticals Inc is led by Todd C. Davis (age 64), CEO & Director, per Nexqual as of June 10, 2026 at 05:13 UTC.
| CEO & Director | Todd C. Davis (age 64) |
|---|---|
| Chief Financial Officer | Octavio Espinoza (age 54) |
| Senior Vice President of Investments & Business Development | Paul J. Hadden |
| Executive Director of Investor Relations and Financial Planning & Analysis | Melanie J. Herman (age 46) |
| Senior Vice President of Biology & Scientific Affairs | Keith Marschke |
Major Backers & Investors (LGND)
Notable institutional backers of Ligand Pharmaceuticals Inc include Janus Henderson Group PLC, Invesco, FMR, LLC, according to Nexqual as of June 10, 2026 at 05:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 5.04% |
| Invesco | 4.11% |
| FMR, LLC | 2.97% |
| Franklin Resources, Inc. | 2.86% |
| Nomura Asset Management International Inc | 2.86% |
| Chicago Capital, LLC | 2.8% |
| Franklin Custodian Funds-FRANKLIN DYNATECH FUND | 2.62% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.04% |
| Vanguard Group | 16.21% |
| State Street | 3.89% |
Source: Nexqual, June 10, 2026 at 05:13 UTC.
From Ligand Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
- It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
- The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes.
- In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NBIX | Neurocrine Biosciences, Inc. | USD 165.24 | ▲ 0.83% |
| INCY | Incyte Corporation | USD 103.23 | ▲ 0.83% |
| ALKS | Alkermes plc | USD 44.29 | ▲ 3.48% |
| MYGN | Myriad Genetics, Inc. | USD 4.54 | ▼ 0.66% |
| UTHR | United Therapeutics Corporation | USD 553.14 | ▲ 0.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:13 UTC. This page is informational and not investment advice.